首頁 > 市場調查報告書 > 製藥

疫苗

市場調查報告書

商品編碼

1900327

禽流感疫苗市場規模、佔有率和成長分析（按疫苗類型、應用、病毒株、給藥途徑、目標類型、通路和地區分類）－2026-2033年產業預測

Avian Influenza Vaccine Market Size, Share, and Growth Analysis, By Vaccine Type, By Application, By Strain, By Administration Route, By Target Species, By Distribution Channel, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月16日 | 出版商:

SkyQuest | 英文 215 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

預計到 2024 年，全球禽流感疫苗市場規模將達到 1,520.1 億美元，到 2025 年將達到 1,583.9 億美元，到 2033 年將達到 2,201.3 億美元，預測期（2026-2033 年）的複合年成長率為 4.2%。

全球禽流感疫苗市場洞察顯示，人們對主要感染家禽、起源於水禽的甲型禽流感病毒高度關注。目前已出現多種亞型，包括H5N1、H7N3、H7N9和H9N2，其中H5N1被認為是致病性最強的。潛在的人類感染凸顯了研發有效疫苗的迫切性。禽流感疫苗依株分為H5、H7和H9疫苗。中國已成為領先的疫苗生產國，其次是美國。隨著全球對禽流感的認知不斷提高，針對特定株的疫苗需求預計將會成長，從而推動疫苗研發領域的進一步投資和創新，以降低相關的健康風險。

全球禽流感疫苗市場促進因素

全球禽流感疫苗市場的主要驅動力是禽流感病毒（尤其是甲型禽流感病毒）的傳播和影響。甲型禽流感病毒在水禽中很流行，但也會感染雞隻和其他家禽。根據其表面蛋白（血凝素和神經氨酸酶）的不同，禽流感病毒可分為多種亞型，並根據致病性分為高致病性和低致病性。非致病性變異株可能引起輕微症狀，而高致病性株則會導致家禽高死亡率，因此，有效的疫苗接種策略對於保護禽群和減少家禽業的經濟損失至關重要。

限制全球禽流感疫苗市場的因素

全球禽流感疫苗市場面臨的主要挑戰在於禽流感病毒的快速變異。這些變異阻礙了有效疫苗接種覆蓋率的維持。病毒的不斷進化需要持續的研究來更好地了解其動態，從而為改進疫苗配方鋪平道路。由於需要不斷創新和投資才能確保疫苗接種工作在對抗不斷變化的病原體方面保持相關性和有效性，因此，疫苗需要根據這些變異進行調整，這構成了市場限制。

全球禽流感疫苗市場趨勢

全球禽流感疫苗市場呈現顯著上升趨勢，尤其是在亞太地區。這主要是由於禽流感病毒在以色列、中國、印度和韓國等主要國家的蔓延。供應鏈效率的提升加快了疫苗供應速度，而強大的研發基礎以及政府的支持政策則加速了疫苗技術的創新。人們對禽流感經濟和健康影響的認知不斷提高，進一步推動了對有效疫苗解決方案的需求。因此，相關人員正積極投資於先進疫苗的研發，以期在這個重要市場中佔據成長優勢。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業的市場定位（2025 年）
主要市場參與者所採取的策略
近期市場趨勢
公司市佔率分析（2025 年）
主要企業公司簡介
- 公司詳情
- 產品系列分析
- 依業務板塊進行公司股票分析
- 2023-2025年營收年比比較

主要企業簡介

Sanofi（France）
GlaxoSmithKline（GSK）（United Kingdom）
Moderna Inc.（United States）
Pfizer Inc.（United States）
AstraZeneca（United Kingdom）
Novavax, Inc.（United States）
Vaxart, Inc.（United States）
BioNTech SE（Germany）
Sinovac Biotech Ltd.（China）
Bharat Biotech International Ltd.（India）
Serum Institute of India Pvt. Ltd.（India）
Daiichi Sankyo Company, Limited（Japan）
Mitsubishi Tanabe Pharma Corporation（Japan）
Seqirus UK Limited（United Kingdom）
Emergent BioSolutions Inc.（United States）
Johnson & Johnson（United States）
Abbott Laboratories（United States）
Roche Holding AG（Switzerland）
Merck & Co., Inc.（United States）

結論與建議

簡介目錄

Product Code: SQMIG35A2886

Global Avian Influenza Vaccine Market size was valued at USD 152.01 Billion in 2024 and is poised to grow from USD 158.39 Billion in 2025 to USD 220.13 Billion by 2033, growing at a CAGR of 4.2% during the forecast period (2026-2033).

Global insights into the avian influenza vaccine market reveal significant concerns surrounding the avian influenza virus type A, primarily affecting domestic poultry and originating from waterfowl. Notably, various subtypes such as H5N1, H7N3, H7N9, and H9N2 have emerged, with H5N1 recognized as the most pathogenic. The transmission potential to humans highlights the urgency of effective vaccine development. The avian influenza vaccine classification includes H5, H7, and H9 vaccines, catering to different strains. China has established itself as a major manufacturer, while the U.S. follows closely. As global awareness of avian influenza grows, the demand for vaccines targeting these specific strains is anticipated to rise, promoting further investment and innovation in vaccine development to mitigate associated health risks.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Avian Influenza Vaccine market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Avian Influenza Vaccine Market Segments Analysis

Global Avian Influenza Vaccine Market is segmented by Vaccine Type, Application, Strain, Administration Route, Target Species, Distribution Channel and region. Based on Vaccine Type, the market is segmented into Inactivated Vaccines, Live Recombinant Vaccines, Combination Vaccines, Recombinant Vaccines and Subunit Vaccines. Based on Application, the market is segmented into Chicken, Duck and Goose, Turkey and Others. Based on Strain, the market is segmented into H5 Strain, H7 Strain and H9 Strain. Based on Administration Route, the market is segmented into Intramuscular, Subcutaneous and Waterborne. Based on Target Species, the market is segmented into Broilers, Layers, Breeders and Backyard Poultry. Based on Distribution Channel, the market is segmented into Veterinary Clinics, Online Pharmacies and Retail Stores. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Avian Influenza Vaccine Market

The global market for avian influenza vaccines is primarily driven by the prevalence and impact of the avian influenza virus, particularly type A, which is frequently found in waterfowl and can infect domestic poultry like chickens. This virus is categorized into various subtypes based on its surface proteins, namely hemagglutinin and neuraminidase, which play a role in its classification as either highly pathogenic or low pathogenic. While nonpathogenic variants may lead to mild symptoms, highly pathogenic strains can result in significant mortality rates in poultry, necessitating effective vaccination strategies to protect bird populations and mitigate economic losses in the poultry industry.

Restraints in the Global Avian Influenza Vaccine Market

A significant challenge in the Global Avian Influenza Vaccine market arises from the swift mutation rate of the avian influenza virus, which hampers efforts to sustain effective vaccine coverage. This constant evolution of the virus necessitates ongoing research to gain a deeper understanding of its dynamics, paving the way for enhancements in vaccine formulations. The need to adapt vaccines to address these mutations poses a restraint on the market, as it demands continuous innovation and investment to ensure that immunization efforts remain relevant and effective in combating this ever-changing pathogen.

Market Trends of the Global Avian Influenza Vaccine Market

The Global Avian Influenza Vaccine market is witnessing a significant upward trend, particularly in the Asia-Pacific region, driven by the prevalence of bird flu viruses in key countries such as Israel, China, India, and South Korea. Enhanced supply chain efficiencies facilitate faster vaccine distribution, while robust research and development infrastructures, supported by favorable government policies, are accelerating innovation in vaccine technology. Increased awareness about the economic and health impacts of avian influenza is further propelling demand for effective vaccination solutions. As a result, stakeholders are actively investing in advanced vaccine developments, positioning themselves for growth in this critical market.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis

Global Avian Influenza Vaccine Market Size by Vaccine Type & CAGR (2026-2033)

Market Overview
Inactivated Vaccines
Live Recombinant Vaccines
Combination Vaccines
Recombinant Vaccines
Subunit Vaccines

Global Avian Influenza Vaccine Market Size by Application & CAGR (2026-2033)

Market Overview
Chicken
Duck and Goose
Turkey
Others

Global Avian Influenza Vaccine Market Size by Strain & CAGR (2026-2033)

Market Overview
H5 Strain
H7 Strain
H9 Strain

Global Avian Influenza Vaccine Market Size by Administration Route & CAGR (2026-2033)

Market Overview
Intramuscular
Subcutaneous
Waterborne

Global Avian Influenza Vaccine Market Size by Target Species & CAGR (2026-2033)

Market Overview
Broilers
Layers
Breeders
Backyard Poultry

Global Avian Influenza Vaccine Market Size by Distribution Channel & CAGR (2026-2033)

Market Overview
Veterinary Clinics
Online Pharmacies
Retail Stores

Global Avian Influenza Vaccine Market Size & CAGR (2026-2033)

North America (Vaccine Type, Application, Strain, Administration Route, Target Species, Distribution Channel)
- US
- Canada
Europe (Vaccine Type, Application, Strain, Administration Route, Target Species, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Vaccine Type, Application, Strain, Administration Route, Target Species, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Vaccine Type, Application, Strain, Administration Route, Target Species, Distribution Channel)
- Brazil
- Rest of Latin America
Middle East & Africa (Vaccine Type, Application, Strain, Administration Route, Target Species, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Sanofi (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline (GSK) (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Moderna Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novavax, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Vaxart, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BioNTech SE (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sinovac Biotech Ltd. (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bharat Biotech International Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Serum Institute of India Pvt. Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Daiichi Sankyo Company, Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mitsubishi Tanabe Pharma Corporation (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Seqirus UK Limited (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Emergent BioSolutions Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Abbott Laboratories (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Roche Holding AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments